Back to all studies
🫁
Phase 3
Respiratory
in-person
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Sponsored by GlaxoSmithKline
Compensation
$500–$2,500
Duration
3 months
Location
Nationwide
About this study
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
Who can participate
- • Adults aged 18–99
- • All genders welcome
- • Diagnosed with or experiencing asthma
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.